Skip to content

AbCellera Biologics Inc. ABCL Available for sale investments

Available for sale investments at other companies

Schrodinger logo
SchrodingerSDGR
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
Precigen logo
PrecigenPGEN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%
Enterprise value$1.88B+100.0%
P/S23.3×-26.8×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s available for sale investments?
AbCellera Biologics Inc. (ABCL) reported available for sale investments of $427.67M in Q1 2026.
How has AbCellera Biologics Inc.'s available for sale investments changed year-over-year?
AbCellera Biologics Inc.'s available for sale investments decreased by 4.1% year-over-year, from $446M to $427.67M.
What is the long-term trend for AbCellera Biologics Inc.'s available for sale investments?
Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s available for sale investments has grown at a 13.2% compound annual growth rate (CAGR), from $246.84M to $405.31M.